Advances in understanding L-DOPA-induced dyskinesia

Curr Opin Neurobiol. 2007 Dec;17(6):665-71. doi: 10.1016/j.conb.2008.01.004. Epub 2008 Mar 4.

Abstract

The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with L-3,4-dihydroxy-phenylalanine (L-DOPA), which however causes excessive involuntary movements in a majority of patients. L-DOPA-induced dyskinesia (abnormal involuntary movements) provides a topic of investigation at the interface between clinical and basic neuroscience. In this article, we review recent studies in rodent models, which have uncovered two principal alterations at the basis of the movement disorder, namely, an abnormal pre-synaptic handling of exogenous L-DOPA, and a hyper-reactive post-synaptic response to DA. Dysregulated nigrostriatal DA transmission causes secondary alterations in a variety of non-dopaminergic transmitter systems, the manipulation of which modulates dyskinesia through mechanisms that are presently unclear. Further research on L-DOPA-induced dyskinesia will contribute to a deeper understanding of the functional interplay between neurotransmitters and neuromodulators in the motor circuits of the basal ganglia.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects*
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dyskinesia, Drug-Induced* / metabolism
  • Dyskinesia, Drug-Induced* / pathology
  • Dyskinesia, Drug-Induced* / physiopathology
  • Humans
  • Levodopa / adverse effects*
  • Models, Neurological
  • Neural Pathways / pathology
  • Synaptic Transmission

Substances

  • Antiparkinson Agents
  • Levodopa
  • Dopamine